PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
6.26
Current Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.86. Joel Greenblatt would see extra liquidity as a cushion for downturns.
5.99
Quick Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.30. Joel Greenblatt would see a superior short-term safety net.
2.68
Cash Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 1.01. Joel Greenblatt might see a strategic advantage in crisis periods.
-11.57
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
0.02
Short-term coverage of 0.02 versus zero Drug Manufacturers - Specialty & Generic median. Walter Schloss would verify if our cash flow management provides advantages.